BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Álvarez MG, Ramírez JC, Bertocchi G, Fernández M, Hernández Y, Lococo B, Lopez-Albizu C, Schijman A, Cura C, Abril M, Laucella S, Tarleton RL, Natale MA, Castro Eiro M, Sosa-Estani S, Viotti R. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up. Antimicrob Agents Chemother 2020;64:e00439-20. [PMID: 32571827 DOI: 10.1128/AAC.00439-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Frade VP, Moreira CHV, Sabino EC, Bedor DCG, Ghilard FDR, Oliveira CDL, Sanches C. Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease. Rev Inst Med trop S Paulo 2022;64:e4. [DOI: 10.1590/s1678-9946202264004] [Reference Citation Analysis]
2 Cruz-Chan JV, Villanueva-Lizama LE, Versteeg L, Damania A, Villar MJ, González-López C, Keegan B, Pollet J, Gusovsky F, Hotez PJ, Bottazzi ME, Jones KM. Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection. Sci Rep 2021;11:3222. [PMID: 33547365 DOI: 10.1038/s41598-021-82930-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Alonso-Vega C, Urbina JA, Sanz S, Pinazo MJ, Pinto JJ, Gonzalez VR, Rojas G, Ortiz L, Garcia W, Lozano D, Soy D, Maldonado RA, Nagarkatti R, Debrabant A, Schijman A, Thomas MC, López MC, Michael K, Ribeiro I, Gascon J, Torrico F, Almeida IC. New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia. BMJ Open 2021;11:e052897. [PMID: 34972765 DOI: 10.1136/bmjopen-2021-052897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hasslocher-Moreno AM, Saraiva RM, Sangenis LHC, Xavier SS, de Sousa AS, Costa AR, de Holanda MT, Veloso HH, Mendes FSNS, Costa FAC, Boia MN, Brasil PEAA, Carneiro FM, da Silva GMS, Mediano MFF. Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study. EClinicalMedicine 2021;31:100694. [PMID: 33554085 DOI: 10.1016/j.eclinm.2020.100694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Castro Eiro MD, Natale MA, Alvarez MG, Castro A, Seigelshifer D, Viotti R, Fernández M, Mazzuoccolo L, Lococo B, Bertocchi GL, Cesar G, Albareda MC, Elias MJ, Caputo MB, Gaddi E, Balbaryski J, Vigliano CA, Laucella SA. Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole. Microbiol Spectr 2022;:e0135722. [PMID: 35938810 DOI: 10.1128/spectrum.01357-22] [Reference Citation Analysis]